Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Study reveals new opportunities for using small molecule drugs to target KRAS mutants

by Medical Finance
in News
NYBC discovers novel small-molecule pancoronavirus fusion inhibitors
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

Research published today in Nature Chemical Biology reveals new opportunities for using small molecule drugs to target KRAS, the most commonly mutated protein in cancer. Promega research scientists collaborated with the University of California – San Francisco research group led by Dr. Kevan M. Shokat, a global leader in KRAS biology, to study the binding of potentially therapeutic molecules to common mutants of the KRAS protein. This study represents the first observation and quantification of direct target engagement of KRAS(G12D) and other hotspot oncogenic mutants of KRAS in cells using reversible binders.

KRAS and cancer

KRAS is a protein that serves as a “master switch” for regulating cell proliferation. It is the most commonly mutated protein in cancer. KRAS was long considered to be “undruggable” until 2013 when the Shokat lab identified covalent drugs targeting KRAS(G12C), a common mutant in which a glycine amino acid is changed to a cysteine. That discovery led to increased drug discovery research, and eventually the first inhibitors targeting KRAS(G12C).

Unfortunately, other mutants of KRAS presented different challenges. All of the known inhibitors of KRAS(G12C) relied on an inactive state of the protein that other mutants do not frequently exhibit. The G12C mutation also provided the opportunity to employ covalent drug discovery methods that would not apply to other hotspot mutants. For those reasons, alleles such as KRAS(G12D) and KRAS(G12V) continued to be considered undruggable.

Targeting hotspot mutants for drug discovery

The research published today in Nature Chemical Biology utilized a Bioluminescence Resonance Energy Transfer (BRET) assay to quantify target engagement of RAS complexes in live cells. They found that the switch-II pocket of KRAS was a privileged drug binding site for non-covalent ligands, and that this was not dependent on the activation state of KRAS. These results open new opportunities for targeting non-G12C mutants of KRAS in drug discovery.

“We’ve shown that some of these highly aggressive mutants are indeed vulnerable to small molecule inhibitors,” says Matt Robers, Senior Research Scientist at Promega.

With our new target engagement method, we can measure binding within living cells and show that the binding we see at these hotspot mutants actually translates into anti-proliferative effects in the pancreatic cancer lineages.”


Matt Robers, Senior Research Scientist, Promega

In addition to the BRET methods for measuring target engagement, the paper also describes nuclear magnetic resonance (NMR) spectroscopy methods for observing reversible ligand binding in vitro and determining the state of the KRAS protein. The authors hope that the methods they describe will be a valuable tool for researchers to develop treatments for some of the most aggressive KRAS mutants previously thought to be “undruggable.”

Promega offers a comprehensive selection of tools to accelerate RAS pathway drug discovery based on a sensitive bioluminescence platform.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

by Medical Finance
May 19, 2022
0

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability...

Scientists discover a division of labor between genetic switches

Genetic variations in critical mitochondrial enzyme play a role in age-related mobility changes

by Medical Finance
May 19, 2022
0

Age-related changes in strength and mobility may depend on genetic variations in a critical mitochondrial enzyme, suggests a study published...

Aceto consolidates acquisition of six manufacturers, strengthening its unique hybrid model that provides major supply chain benefits to customers

Researchers use electricity to design tool that may help to create pharmaceutical compounds

by Medical Finance
May 19, 2022
0

What do gunpowder, penicillin and Teflon all have in common? They were inventions that took the world by storm, but...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

UNIGE scientists develop a novel tool to visualize palmitoylation process in living cells

by Medical Finance
May 19, 2022
0

Peripheral membrane proteins have the particularity of temporarily binding to cell membranes, a necessary step for them to be able...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Study offers a path to closing the knowledge gap about differences in breast cancer genes

by Medical Finance
May 19, 2022
0

Too many women are getting unnecessary mastectomies and other invasive procedures because of a knowledge gap about differences in cancer...

Study identifies cellular receptors for alphaviruses shared across mosquitoes, humans, and animals

Gut virome may warn of a serious and often fatal disease in preterm infants

by Medical Finance
May 19, 2022
0

Immediately after birth, human infants begin to develop a complex, interwoven fabric of microbes in their gut. Known collectively as...

Next Post
Nutritional components hold promise for improving the health and well-being of adults

Molecular RNA profile of naked mole-rats reveals new insights on skin aging

Study: Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease. Image Credit: SKK Pix / Shutterstock

Compound found in Datura shows promise as antiviral agent against SARS-CoV-2

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Research Letter: Seroprevalence of Antibodies Specific to Receptor Binding Domain of SARS-CoV-2 and Vaccination Coverage Among Adults in Los Angeles County, April 2021: The LA Pandemic Surveillance Cohort Study. Image Credit: ktsdesign/Shutterstock
    LA County study finds COVID-19 ‘herd immunity’ unlikely
  • Study: Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. Image Credit: Vitalii Vodolazskyi/Shutterstock
    Hypoxia-inducible factors and SARS-CoV-2 manifestations
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply